Zinc therapy in Wilson's disease

Observations in five patients

L. Rossaro, G. C. Sturniolo, G. Giacon, M. C. Montino, P. E. Lecis, R. R. Schade, G. R. Corazza, C. Trevisan, R. Naccarato

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We report our experience with zinc (Zn) therapy in five patients with Wilson's disease (WD). In addition to neurologic examination, evaluation of Kayser-Fleischer rings and liver function tests, copper (Cu) and Zn concentrations in liver tissue, plasma, and urine were periodically evaluated by spectrophotometry. Many of the patients had had side effects due to penicillamine (PCA). Oral Zn sulphate (220 mg tid) reduced the WD symptoms and resulted in normal urinary Cu excretion in all five patients. One patient who had a transient gastric complaint during Zn administration, and in whom a decrease in liver Cu content was not observed, did not show any improvement in liver histology. He resumed PCA therapy after 29 months of Zn therapy. We conclude that long-term Zn treatment in Wilson's disease can be safe and effective alternative to Cu chelating agents. However, patients should be periodically monitored for their Cu/Zn status to assess patient compliance with therapy.

Original languageEnglish
Pages (from-to)665-668
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume85
Issue number6
Publication statusPublished - 1990

Fingerprint

Hepatolenticular Degeneration
Zinc
Penicillamine
Liver
Therapeutics
Zinc Sulfate
Spectrophotometry
Liver Function Tests
Neurologic Examination
Patient Compliance
Chelating Agents
Copper
Stomach
Histology
Urine

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rossaro, L., Sturniolo, G. C., Giacon, G., Montino, M. C., Lecis, P. E., Schade, R. R., ... Naccarato, R. (1990). Zinc therapy in Wilson's disease: Observations in five patients. American Journal of Gastroenterology, 85(6), 665-668.

Zinc therapy in Wilson's disease : Observations in five patients. / Rossaro, L.; Sturniolo, G. C.; Giacon, G.; Montino, M. C.; Lecis, P. E.; Schade, R. R.; Corazza, G. R.; Trevisan, C.; Naccarato, R.

In: American Journal of Gastroenterology, Vol. 85, No. 6, 1990, p. 665-668.

Research output: Contribution to journalArticle

Rossaro, L, Sturniolo, GC, Giacon, G, Montino, MC, Lecis, PE, Schade, RR, Corazza, GR, Trevisan, C & Naccarato, R 1990, 'Zinc therapy in Wilson's disease: Observations in five patients', American Journal of Gastroenterology, vol. 85, no. 6, pp. 665-668.
Rossaro L, Sturniolo GC, Giacon G, Montino MC, Lecis PE, Schade RR et al. Zinc therapy in Wilson's disease: Observations in five patients. American Journal of Gastroenterology. 1990;85(6):665-668.
Rossaro, L. ; Sturniolo, G. C. ; Giacon, G. ; Montino, M. C. ; Lecis, P. E. ; Schade, R. R. ; Corazza, G. R. ; Trevisan, C. ; Naccarato, R. / Zinc therapy in Wilson's disease : Observations in five patients. In: American Journal of Gastroenterology. 1990 ; Vol. 85, No. 6. pp. 665-668.
@article{03775dafde514357a594221234f484a5,
title = "Zinc therapy in Wilson's disease: Observations in five patients",
abstract = "We report our experience with zinc (Zn) therapy in five patients with Wilson's disease (WD). In addition to neurologic examination, evaluation of Kayser-Fleischer rings and liver function tests, copper (Cu) and Zn concentrations in liver tissue, plasma, and urine were periodically evaluated by spectrophotometry. Many of the patients had had side effects due to penicillamine (PCA). Oral Zn sulphate (220 mg tid) reduced the WD symptoms and resulted in normal urinary Cu excretion in all five patients. One patient who had a transient gastric complaint during Zn administration, and in whom a decrease in liver Cu content was not observed, did not show any improvement in liver histology. He resumed PCA therapy after 29 months of Zn therapy. We conclude that long-term Zn treatment in Wilson's disease can be safe and effective alternative to Cu chelating agents. However, patients should be periodically monitored for their Cu/Zn status to assess patient compliance with therapy.",
author = "L. Rossaro and Sturniolo, {G. C.} and G. Giacon and Montino, {M. C.} and Lecis, {P. E.} and Schade, {R. R.} and Corazza, {G. R.} and C. Trevisan and R. Naccarato",
year = "1990",
language = "English",
volume = "85",
pages = "665--668",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Zinc therapy in Wilson's disease

T2 - Observations in five patients

AU - Rossaro, L.

AU - Sturniolo, G. C.

AU - Giacon, G.

AU - Montino, M. C.

AU - Lecis, P. E.

AU - Schade, R. R.

AU - Corazza, G. R.

AU - Trevisan, C.

AU - Naccarato, R.

PY - 1990

Y1 - 1990

N2 - We report our experience with zinc (Zn) therapy in five patients with Wilson's disease (WD). In addition to neurologic examination, evaluation of Kayser-Fleischer rings and liver function tests, copper (Cu) and Zn concentrations in liver tissue, plasma, and urine were periodically evaluated by spectrophotometry. Many of the patients had had side effects due to penicillamine (PCA). Oral Zn sulphate (220 mg tid) reduced the WD symptoms and resulted in normal urinary Cu excretion in all five patients. One patient who had a transient gastric complaint during Zn administration, and in whom a decrease in liver Cu content was not observed, did not show any improvement in liver histology. He resumed PCA therapy after 29 months of Zn therapy. We conclude that long-term Zn treatment in Wilson's disease can be safe and effective alternative to Cu chelating agents. However, patients should be periodically monitored for their Cu/Zn status to assess patient compliance with therapy.

AB - We report our experience with zinc (Zn) therapy in five patients with Wilson's disease (WD). In addition to neurologic examination, evaluation of Kayser-Fleischer rings and liver function tests, copper (Cu) and Zn concentrations in liver tissue, plasma, and urine were periodically evaluated by spectrophotometry. Many of the patients had had side effects due to penicillamine (PCA). Oral Zn sulphate (220 mg tid) reduced the WD symptoms and resulted in normal urinary Cu excretion in all five patients. One patient who had a transient gastric complaint during Zn administration, and in whom a decrease in liver Cu content was not observed, did not show any improvement in liver histology. He resumed PCA therapy after 29 months of Zn therapy. We conclude that long-term Zn treatment in Wilson's disease can be safe and effective alternative to Cu chelating agents. However, patients should be periodically monitored for their Cu/Zn status to assess patient compliance with therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025289293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025289293&partnerID=8YFLogxK

M3 - Article

VL - 85

SP - 665

EP - 668

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -